1. Baldridge EB, Bessen HA. Phencyclidine. Emergency Med Clin North Am 1990;8:541–550.

2. Balster RL. The behavioral pharmacology of phencyclidine. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;1573–1579.

3. Balster RL. Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In: Glennon RA, Järbe TUC, Frankenheim J, eds. Drug discrimination: applications to drug abuse research. National Institute on Drug Abuse Research Monograph Series 116. DHHS publication no. (ADM) 92-1878. Washington, DC: U.S. Government Printing Office, 1991;163–180.

4. Balster RL, Nicholson KL, Sanger DJ. Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats. Drug Alcohol Depend, 1994;[in press].

5. Brecher M, Wang BW, et al. Phencyclidine and violence: clinical and legal issues. J Clin Psychopharmacol 1988;8:397–401.

6. Bristow LJ, Hutson PH, Thorn HL, Trickelbank MD. The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol 1993;108: 1156–1163.

7. Busto U, Bendayan R, and Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clinical Pharmacokinetics 1989;16: 1–26.

8. Carroll ME. PCP and hallucinogens. Adv Alcohol Subst Abuse 1990;9:167–190.

9. Carroll ME. The economic context of drug and non-drug reinforcers affects acquisition and maintenance of drug-reinforced behavior and withdrawal effects. Drug Alcohol Depend 1993;33:201–210.

10. Carroll ME, Carmona G. Effects of food FR and food deprivation on disruptions in food-maintained performance of monkeys during phencyclidine withdrawal. Psychopharmacology 1991;104: 143–149.

11. Contreras PC, Gray NM, DiMaggio DA, et al. Isolation and characterization of an endogenous ligand for the PCP and receptors from porcine, rat, and human tissue. Sigma, PCP, and NMDA receptors. National Institute on Drug Abuse Research Monograph Series 133. NIH publication no. 93-3587. Washington, DC: U.S. Government Printing Office, 1993;207–223.

12. Cosgrove J, Newell TG. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 1991;47:159–169.

13. Daghestani AN, Schnoll SH. Phencyclidine abuse and dependence. Treatments of psychiatric disorders, vol 2. A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association 1989;1209–1218.

14. De Sarro GB, De Sarro A. Anticonvulsant properties of noncompetitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology 1993;32:51–68.

15. Dimpfel W, Spuler M. Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Psychopharmacology 1990;101:317–323.

16. Done AK, Aronow R, Miceli JN. Pharmacokinetic bases for the diagnosis and treatment of acute PCP intoxication. J Psychedelic Drugs 1980;12:253–258.

17. France CP, Snyder AM, Woods JH. Analgesic effects of phencyclidine-like drugs in rhesus monkeys. J Pharmacol Exp Ther 1989;250:197–201.

18. French ED, Mura A, Wang T. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: Comparison to competitive NMDA antagonists. Synapse 1993; 13:108–116.

19. Giannini AJ, Loiselle RH, Graham BH, et al. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. J Subst Abuse Treat 1993;10:523–527.

20. Giannini AJ, Malone DA, Giannini MC, et al. Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. J Clin Pharmacol 1986;26:211–214.

21. Glantz JC, Woods JR. Cocaine, heroin, and phencyclidine: obstetric perspectives. Clin Obstet Gynecol 1993;36:279–301.

22. Gorelick DA, Wilkins JN. Inpatient treatment of PCP abusers and users. Am J Drug Alcohol Abuse 1989;15:1–12.

23. Gorelick DA, Wilkins JN, Wong C. Outpatient treatment of PCP abusers. Am J Drug Alcohol Abuse 1989;15:367–374.

24. Gwirtsman HE, Wittkop W, Gorelick DA, et al. Phencyclidine intoxication incidence, clinical patterns, and course of treatments. Res Commun Psychol Psychiatry Behav 1984;9:405–410.

25. Hertzman M, Reba RC, Kotlyarove EV. Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry 1990;147:255–256.

26. Holsztynska EJ, Weber WW, Domino EF. Genetic polymorphism of cytochrome P-450-dependent phencyclidine hydroxylation in mice. Drug Metab Disposition, 1991;19:48–53.

27. Itzhak Y. Different modulation of the binding to two phencyclidine (PCP) receptor subtypes: effects of N-methyl-D-aspartate agonists and antagonists. Neurosci Lett 1989;104:314–319.

28. Jamieson GA, Agrawal AK, Greco NJ, et al. Phencyclidine binds to blood platelets with high affinity and specifically inhibits their activation by adrenaline. Biochem J 1992;285:35–39.

29. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–1308.

30. Johnson KM, Jones SM. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 1990;30:707–750.

31. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from the Monitoring the Future Study, 1975–1992. National Institutes of Health, Publication no. 93-3598, 1993.

32. Karler R, Calder LD, Chaudhry IA, Turkanis SA. Blockade of reverse tolerance to cocaine and amphetamine by MK-801. Life Sci 1989;45:599–606.

33. Keith VA, Mansbach RS, Geyer MA. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991;30:557–566.

34. Krystal JH, Karper L, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine in humans. Arch Gen Psychiatry 1994;51:199–214.

35. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990;11:81–86.

36. Lyddane JE, Thomas BF, Compton DR, et al. Modification of phencyclidine intoxification and biodisposition by charcoal and other treatments. Pharmacol Biochem Behav 1988;30:371–377.

37. Maguire K, Pastore AL, Flanagan TJ, eds. Sourcebook of criminal justice statistics, 1994. Washington, DC: U.S. US Dept of Justice, Bureau of Justice Statistics, 1993.

38. Manallack DT, Davies JW, Beart PM, Saunders MR, Livingstone DJ. Analysis of the biological and molecular properties of phencyclidine-like compounds by chemometrics. Arzneimittelforschung 1993;43:1029–1032.

39. Mansbach RS, Willetts J, Jortani SA, Balster RL. NMDA antagonists: lack of an antipunishment effect in squirrel monkeys. Pharmacol Biochem Behav 1991;39:977–981.

40. Maren S, Baudry M, Thompson RF. Differential effects of ketamine and MK-801 on the induction of long-term potentiation. Neuroreport 1991;2:239–242.

41. Martin BR, Boni J. Pyrolysis and inhalation studies with phencyclidine and cocaine. Research findings on smoking of abused substances. NIDA Research Monograph 99. Washington, DC: NIDA, 1990;141–158.

42. Massey BM, Wessinger WD. Alterations in rat brain [3H]-TCP binding following chronic phencyclidine administration. Life Sci 1990;47:139–143.

43. Mattson MP, Rychlik B, Cheng B. Degenerative and axon outgrowth-altering effects of phencyclidine in human fetal cerebral cortical cells. Neuropharmacology 1992;31:279–291.

44. Maurice T, Vignon J, Kamenka JM, Chicheportiche R. Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J Neurochem 1991;56:533–559.

45. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989;29:365–402.

46. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991;354:31–37.

47. Musacchio JM. The psychotomimetic effects of opiates and the s receptor. Neuropsychopharmacology 1990;3:191–200.

48. NIDA Statistical Series, Series I, Number 11-A. Annual emergency room data, 1991. DHHS publication no. (ADM) 92-1955, 1992.

49. NIDA Statistical Series, Series I, Number 11-B. Annual medical examiner data, 1991. DHHS publication no. (ADM) 92-1956, 1992.

50. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360–1362.

51. Pearlson GD. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 1981;148: 25–33.

52. Pillai R, Nair BS, Watson RR, et al. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991;65:609–617.

53. Pitts FN, Allen RE, Aniline O, et al. Occupational intoxication and long-term persistence of phencyclidine (PCP) in law enforcement personnel. Clin Toxicol 1981;18:1015–1020.

54. Pohorecki R, Rayburn W, Coon WW, et al. Some factors affecting phencyclidine biotransformation by human liver and placenta. Drug Metab Dispos 1989;17:271–274.

55. Price WA, Giannini AJ, Krishen A. Management of acute PCP intoxication with verapamil. Clin Toxicol 1986;24:85–87.

56. Quirion R, Chicheportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, Woods JH, Zukin SR. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 1987;10:444–446.

57. Rahbar F, Fomufod A, White D, et al. Impact of intrauterine exposure to phencyclidine (PCP) and cocaine on neonates. J Natl Med Assoc 85:349–352.

58. Rao TS, Kim HC, Lehmann J, Martin LL, Wood PL. Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methylD-aspartate (NMDA) receptors. Neuropharmacology 1990;29: 225–230.

59. Renfroe CL, Messinger TA. Street drug analysis: an eleven year perspective on illicit drug alteration. Semin Adolesc Med 1985;1:247–257.

60. Rothman RB, Reid AA, Monna JA, Jacobson AE, Rice KC. The psychotomimetic drug phencyclidine labels 2 high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol Pharmacol 1989;36:887–896.

61. Schwartz RH. Passive inhalation of marijuana, phencyclidine, and freebase. Am J Dis Child 1989;143:644.

62. Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991;9:336–342.

63. Shoaib M, Stolerman IP. MK-801 attenuates behavioural adaptation to chronic nicotine administration in rats. Br J Pharmacol 1991;105:514–515.

64. Simpson GM, Khajawall AM, Alatorre E, et al. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982–1983;19:1051–1059.

65. Singh L, Menzies R, Tricklebank MD. The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor. Eur J Pharmacol 1990;186:129–132.

66. Sioris L, Krenzelok E. Phencyclidine intoxication: literature review. Am J Hosp Pharm 1978;35:1362–1367.

67. Smith JB. Situational specificity of tolerance to effects of phencyclidine on responding of rats under fixed-ratio and spaced-responding schedules. Psychopharmacology 1991;103:121–128.

68. Steinpreis RE, Salamone JD. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res 1993;612:263–270.

69. Sveinbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS. The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993;16:165–174.

70. Tabor BL, Smith-Wallace T, Yonekura ML. Perinatal outcome associated with PCP versus cocaine use. Am J Drug Alcohol Abuse 1990;16:337–348.

71. Thurkauf A, Zenk PC, Balster RL, May EL, George C, Caroll FI, Mascarella SW, Rice KC, Jacobson AE, Mattson MV. Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist. J Med Chem 1988;31: 2257–2263.

72. Tiseo PJ, Inturrisi CE. Attenuation and reversal of morphine tolerance by competitive N-methyl-D-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 1992;264:1090–1096.

73. Troupin AS, Mendius JR, Cheng F, Risinger MW. MK-801. In: Meldrum B, Porter R, eds. New Anticonvulsant drugs. London: John Libby, 1986;191–201.

74. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251:85–87.

75. Van Dyke DC, Fox AA. Fetal drug exposure and its possible implications for learning in the preschool and school-age population. J Learn Disabil 1990;23:160–163.

76. Wachsman L, Schuetz S, Chan LS, et al. What happens to babies exposed to phencyclidine (PCP) in utero? Am J Drug Alcohol Abuse 1989;15:31–39.

77. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa R, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990;42:355–402.

78. Wang T, French ED. Effects of phencyclidine on spontaneous and excitatory amino acid-induced activity of ventral tegmental dopamine neurons: an extracellular in vitro study. Life Sci 1993;53: 49–56.

79. Weissman AD, Casanova MF, Kleinman JE, DeSouza EB. PCP and sigma receptors in brain are not altered after repeated exposure to PCP in humans. Neuropsychopharmacology 1991;4:95–102.

80. Wessinger SD, Owens SM. Phencyclidine dependence: The relationship of dose and serum concentrations to operant behavior effects. J Pharmacol Exp Ther 1991;258:207–215.

81. Wiley JL, Balster RL. Preclinical evaluation of N-methyl-Daspartate antagonists for antianxiety effects: a review. In: Kamenka J-M, Domino EF, eds. Multiple sigma and PCP receptor ligands: mechanisms for neuromodulation and neuroprotection? Ann Arbor, MI: NPP Books, 1992;801–815.

82. Willetts J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 1990;11:423–428.

83. Woods JH, Koek W, France CP, Moerschbaecher JM. Behavioural effects of NMDA antagonists. In: Meldrum BS, ed. Excitatory amino acid antagonists. Oxford: Blackwell Scientific Publications, 1991;237–264.

84. Wu JC, Buchsbaum MS, Bunney WE. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Jpn J Psychopharmacol 1991;11:47–48.

85. Yamakura T, Mori H, Masaki H, Shimoji K, Mishina M. Different sensitivities of NMDA receptor channel subtypes to noncompetitive antagonists. Neuroreport 1993;4:687–90.

86. Young T, Lawson GW, et al. Clinical aspects of phencyclidine (PCP). Int J Addict 1987;22:1–15.

87. Zukin RS, Zukin SR. Phencyclidine, s and NMDA receptors: Emerging concepts. In: Domino EF, Kamenka J-M, eds. Sigma and phencyclidine-like compounds as molecular probes in biology. Ann Arbor, MI: NPP Books, 1988;407–424.